<?xml version="1.0" encoding="UTF-8"?>
<p>However, further studies are still needed to draw conclusions because most of these studies bear limitations including selection bias, allocation bias, or insufficient case numbers. Several multicenter, double-blind, and well-designed controlled trials are already underway to assess the efficacy and safety of CQ or HCQ in the treatment of COVID-19 pneumonia. In the absence of other confirmed effective therapy specific to SARS-CoV-2, both drugs are currently still listed in the treatment guidelines (
 <xref rid="table1-1759720X20947296" ref-type="table">Table 1</xref>).
</p>
